{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 1 or 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2"},{"groupId":"OG001","value":"100"}]}],"title":"Grade 0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Renal function was assessed using glomerular filtration rate (GFR) based on age measure; Modification of Diet in Renal Disease (MDRD) formula for participants aged 18 years or older, defined as GFR equal to 32788\\*(serum creatinine (micromol/L)\\^-1.154)\\*(age\\^-0.203 )\\*(0.742, if female)\\*(1.210, if black), and Schwartz formula for participants less than 18 years defined as GFR equal to 0.41\\*height (cm)/ Serum creatinine (mg/dL). Participants with severe renal impairment defined as GFR \\< 30 mL/min/1.73 m\\^2 and participants with National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 3/4 serum creatinine were reported.","groups":[{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.","id":"OG000","title":"Everolimus (Core Period)"},{"description":"Participants received oral dose of placebo matching to everolimus daily.","id":"OG001","title":"Placebo (Core Period)"}],"paramType":"NUMBER","populationDescription":"The analysis was performed in the SAF population. Here, \"Number of participants analysed\" signifies the participants assessed for renal function during the study for each arm, respectively.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 28 days after end of treatment (Core period)","title":"Percentage of Participants With Renal Impairment During Core Period","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}